secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001576885-23-000039
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen shareholders approve officer exculpation amendment; re-elect directors
-----------------------------------------------------------------------------

- Shareholders approved certificate amendment to allow officer exculpation per Delaware law (27,061,448 votes for, 99.9% of votes cast).
- Re-elected Dr. Derrell Porter (27,096,949 for) and Dr. Laura Stoppel (24,440,807 for) as Class II directors until 2026.
- Ratified Ernst & Young as independent auditor for FY2023 with 36,099,071 votes for, 185 against, 214 abstained.
- Quorum of 36,099,470 shares (87.99% of 41,025,062 outstanding) present at annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000039/0001576885-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000039/abos-20230606.htm
  HTML page:      https://secwatch.observer/filing/0001576885-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer